Literature DB >> 25648349

Polymicrobial bacterial or fungal infections: incidence, spectrum of infection, risk factors, and clinical outcomes from a large hematopoietic stem cell transplant center.

S Trifilio1, Z Zhou, J L Fong, A Zomas, D Liu, C Zhao, J Zhang, J Mehta.   

Abstract

BACKGROUND: Infections cause significant morbidity and mortality for patients who undergo hematopoietic stem cell transplantation (HSCT). Cancer patients who develop polymicrobial infection (PI) are at increased risk for poor clinical outcomes, yet very limited data have been published within the HSCT setting.
METHODS: An observational study of 901 stem cell transplant recipients was conducted at Northwestern Memorial Hospital to identify the incidence, risk factors and outcomes for HSCT recipients who develop infection(s) with multiple bacterial or fungal organisms.
RESULTS: Among 901 HSCT recipients reviewed (675 autografts and 226 allografts), 237 patients (27%) had microbiologically documented microorganisms isolated, including 179 patients (76%) with monomicrobial infection and 59 patients (24%) with multiple microorganisms, of which 34 (14%) were classified as PI, and 25 (10%) as multiple distinct episodes of infection.
CONCLUSION: The results show co-infection with multiple organisms during HSCT is relatively rare; however, these patients are at an increased risk for the development of acute graft-versus-host disease, delayed engraftment, and overall mortality.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  graft-versus-host disease; polymicrobial infection; stem cell transplantation

Mesh:

Substances:

Year:  2015        PMID: 25648349     DOI: 10.1111/tid.12363

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  8 in total

Review 1.  "It Takes a Village": Mechanisms Underlying Antimicrobial Recalcitrance of Polymicrobial Biofilms.

Authors:  Giulia Orazi; George A O'Toole
Journal:  J Bacteriol       Date:  2019-12-06       Impact factor: 3.490

2.  Assessment of persistent antimicrobial and anti-biofilm activity of p-HEMA hydrogel loaded with rifampicin and cefixime.

Authors:  Ola Tarawneh; Hadeel Abu Mahfouz; Lama Hamadneh; Ahmad A Deeb; Iyad Al-Sheikh; Wasan Alwahsh; Abdulqader Fadhil Abed
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

3.  A fresh look at polymicrobial bloodstream infection in cancer patients.

Authors:  Cristina Royo-Cebrecos; Carlota Gudiol; Carmen Ardanuy; Helena Pomares; Mariona Calvo; Jordi Carratalà
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

4.  Revisiting Infectious Complications Following Total Parenteral Nutrition Use During Hematopoietic Stem Cell Transplantation.

Authors:  Halina Rubin; Jayesh Mehta; Jessica L Fong; Deborah Greenberg; Solomiya GrusChak; Steven Trifilio
Journal:  J Adv Pract Oncol       Date:  2020-09-01

5.  Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis.

Authors:  Sarah Weber; Aaron Magh; Michael Hogardt; Volkhard A J Kempf; Maria J G T Vehreschild; Hubert Serve; Sebastian Scheich; Björn Steffen
Journal:  Ann Hematol       Date:  2021-05-03       Impact factor: 3.673

6.  Clinical Application of Metagenomic Next-Generation Sequencing for Suspected Infections in Patients With Primary Immunodeficiency Disease.

Authors:  Wenjing Tang; Yu Zhang; Chong Luo; Lina Zhou; Zhiyong Zhang; Xuemei Tang; Xiaodong Zhao; Yunfei An
Journal:  Front Immunol       Date:  2021-08-13       Impact factor: 7.561

7.  Diagnostic value and clinical application of next-generation sequencing for infections in immunosuppressed patients with corticosteroid therapy.

Authors:  Sen Wang; Jingwen Ai; Peng Cui; Yimin Zhu; Honglong Wu; Wenhong Zhang
Journal:  Ann Transl Med       Date:  2020-03

8.  Weakest-Link Dynamics Predict Apparent Antibiotic Interactions in a Model Cross-Feeding Community.

Authors:  Elizabeth M Adamowicz; William R Harcombe
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.